Literature DB >> 19619518

Delta opioid agonist [D-Ala2, D-Leu5] enkephalin (DADLE) reduced oxygen-glucose deprivation caused neuronal injury through the MAPK pathway.

Sun Ke1, Su Dian-san, Wang Xiang-rui.   

Abstract

It has been demonstrated that [D-Ala2, D-Leu5] enkephalin (DADLE), a delta opioid agonist, protected neuron from hypoxic neuronal injury by activating the delta opioid receptor (DOR). However, whether DADLE can prevent neuronal injury induced by severe hypoxia like oxygen-glucose deprivation (OGD) is not clear. Here, we investigated whether DADLE has a protective effect against neuronal injury induced by oxygen-glucose deprivation. Neuron viability was measured by MTT and neuron injury was assessed by lactate dehydrogenase (LDH) release. Protein expression was examined by Western blot. The results showed that DADLE protected the cortical neuron in a dose-dependent way from OGD injury. And this neuroprotective effect could be completely blocked by delta 2 opioid antagonist Naltrindole. DADLE increased phosphorylation of ERK and prevented OGD-induced p38 phosphorylation. Neither DADLE nor Naltrindole had any appreciable effect on phosphorylation of JNK. One of the protective mechanisms of DADLE on OGD neurons may be due to the dynamic balance between the activation of ERK and the p38.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619518     DOI: 10.1016/j.brainres.2009.06.104

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

1.  Prolonged DADLE exposure epigenetically promotes Bcl-2 expression and elicits neuroprotection in primary rat cortical neurons via the PI3K/Akt/NF-κB pathway.

Authors:  Min Zhu; Ming Liu; Qi-Lin Guo; Cui-Qing Zhu; Jing-Chun Guo
Journal:  Acta Pharmacol Sin       Date:  2018-05-24       Impact factor: 6.150

2.  δ-Opioid receptors up-regulate excitatory amino acid transporters in mouse astrocytes.

Authors:  Jianfeng Liang; Dongman Chao; Harleen K Sandhu; Yanbing Yu; Li Zhang; Gianfranco Balboni; Dong H Kim; Ying Xia
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

3.  Alleviating brain stress: what alternative animal models have revealed about therapeutic targets for hypoxia and anoxia.

Authors:  Sarah L Milton; Ken Dawson-Scully
Journal:  Future Neurol       Date:  2013

4.  Delta-opioid receptor activation prolongs respiratory motor output during oxygen-glucose deprivation in neonatal rat spinal cord in vitro.

Authors:  S M F Turner; S M Johnson
Journal:  Neuroscience       Date:  2011-05-06       Impact factor: 3.590

Review 5.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 6.  Delta Opioids: Neuroprotective Roles in Preclinical Studies.

Authors:  Shahid Husain
Journal:  J Ocul Pharmacol Ther       Date:  2018 Jan/Feb       Impact factor: 2.671

Review 7.  Neuroprotection against hypoxia/ischemia: δ-opioid receptor-mediated cellular/molecular events.

Authors:  Xiaozhou He; Harleen K Sandhu; Yilin Yang; Fei Hua; Nathalee Belser; Dong H Kim; Ying Xia
Journal:  Cell Mol Life Sci       Date:  2012-09-27       Impact factor: 9.261

8.  δ-Opioid receptor activation ameliorates lipopolysaccharide-induced inflammation and apoptosis by inhibiting the MAPK/caspase-3 pathway in BV2 microglial cells.

Authors:  Min Cheng; Yue Geng; Yeting Chen; Yongjie Zhang; Runjie Guo; Hong Xu; Jianfeng Liang; Jiajun Xie; Zean Zhang; Xuesong Tian
Journal:  Exp Brain Res       Date:  2020-11-18       Impact factor: 1.972

9.  Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model.

Authors:  Yasir Abdul; Naseem Akhter; Shahid Husain
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-11       Impact factor: 4.799

10.  Delta opioid receptor and its peptide: a receptor-ligand neuroprotection.

Authors:  Meaghan Staples; Sandra Acosta; Naoki Tajiri; Mibel Pabon; Yuji Kaneko; Cesar V Borlongan
Journal:  Int J Mol Sci       Date:  2013-08-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.